We have not examined individual peptides on a sub-protein level in our analysis, but in view of these previous results, decrease of PGLYRP1 under Ruxo treatment might not necessarily point out PGLYRP1 as a direct target of Ruxo, but rather indicate resolution of the ARDS-causing cytokine storm within several days. The gene discussed is PGLYRP1; the disease is acute respiratory distress syndrome.